2. Academic Validation
  3. Harnessing the FBXW7 somatic mutant R465C for targeted protein degradation

Harnessing the FBXW7 somatic mutant R465C for targeted protein degradation

  • bioRxiv. 2024 Dec 4:2024.12.03.626601. doi: 10.1101/2024.12.03.626601.
Ananya A Basu 1 2,  Chenlu Zhang 1,  Milad Rouhimoghadam 3,  Anil Vasudevan 3,  Justin M Reitsma 3,  Xiaoyu Zhang 1 2 4 5 6
Affiliations

Affiliations

  • 1 Department of Chemistry, Northwestern University, Evanston, IL 60208.
  • 2 Chemistry of Life Processes Institute, Northwestern University, Evanston, IL 60208.
  • 3 Technology & Therapeutic Platforms, AbbVie Incorporated, North Chicago, IL 60064.
  • 4 Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611.
  • 5 Center for Human Immunobiology, Northwestern University, Chicago, IL 60611.
  • 6 International Institute for Nanotechnology, Northwestern University, Evanston, IL 60208.
PMID: 39677626 DOI: 10.1101/2024.12.03.626601
Abstract

Targeted protein degradation (TPD) is a pharmacological strategy that eliminates specific proteins from cells by harnessing cellular proteolytic degradation machinery. In proteasome-dependent TPD, expanding the repertoire of E3 Ligases compatible with this approach could enhance the applicability of this strategy across various biological contexts. In this study, we discovered that a somatic mutant of FBXW7, R465C, can be exploited by heterobifunctional compounds for targeted protein degradation. This work demonstrates the potential of utilizing mutant E3 Ligases that occur exclusively in diseased cells for TPD applications.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-173082
    PROTAC FKBP12降解剂
我们的 Cookie 政策

我们使用 Cookies 和类似技术以提高网站的性能和提升您的浏览体验，部分功能也使用 Cookies 帮助我们更好地理解您的需求，为您提供相关的服务。 如果您有任何关于我们如何处理您个人信息的疑问，请阅读我们的《隐私声明》。

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z